Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial

Overview

About this study

The purpose of this study is to evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at High Risk for aortic valve replacement surgery.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. 70 years of age or older
  2. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec
  3. Symptomatology due to aortic stenosis resulting in one of the following:
    1. NYHA Functional Classification of II or greater
    2. Presence of angina
    3. Presence of syncope
  4. Aortic valve annular diameter ≥ 24 and ≤26 mm measured by MSCT based on area or perimeter
  5. STS score of ≥8, or documented heart team agreement of high risk for surgical aortic valve replacement (SAVR) due to frailty or comorbidities.
  6. Geographically available, willing to comply with follow up and able to provide written informed consent

Exclusion Criteria:

  1. Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.
  2. Patients at high risk for coronary obstruction in the opinion of the investigator (e.g. combination of a coronary height < 12 mm and coronary sinus diameter < 30 mm)
  3. Patients with low flow/low gradient aortic stenosis
  4. Patients with significant annular calcification (e.g. Agatston score > 4000)
  5. Pre-existing prosthetic heart valve in any position, or prosthetic ring
  6. Severe aortic, mitral or tricuspid valve regurgitation
  7. Moderate to severe mitral stenosis
  8. Myocardial infarction within the past 30 days*
  9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  10. LVEF < 30%
  11. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure
  12. Hemodynamic instability requiring inotropic drug therapy within the past 14 days
  13. Untreated clinically significant coronary artery disease requiring revascularization
  14. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery
  15. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy
  16. Patient ineligible for or refuses blood transfusions
  17. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or vessels < 6 mm) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
  18. Active peptic ulcer or gastrointestinal bleeding within the past 90 days*
  19. Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 month, or treatment of carotid stenosis within past two months*
  20. Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis
  21. Active infection requiring ongoing treatment
  22. Need for emergent surgery or intervention other than the investigational procedure
  23. Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, except for PCI which is within 7 days of the index procedure*
  24. Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated
  25. Life expectancy < 1 year due to non-cardiac co-morbid conditions
  26. Currently participating in any investigational drug or device studies that may confound the results of this study
  27. History of any cognitive or mental health status that would interfere with study participation
  28. Following surgical consultation, patient is deemed inoperable in the event that surgical intervention is required after HLT valve implantation attempt.
    • At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Gurpreet Sandhu, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20402167

Mayo Clinic Footer